Cellular Biomedicine Group (CBMG) & The Competition Head-To-Head Analysis
Cellular Biomedicine Group (NASDAQ: CBMG) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Cellular Biomedicine Group to similar businesses based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, valuation and dividends.
This table compares Cellular Biomedicine Group and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Biomedicine Group||-12,736.68%||-41.33%||-39.53%|
|Cellular Biomedicine Group Competitors||-5,541.07%||-487.39%||-43.51%|
This is a breakdown of current recommendations for Cellular Biomedicine Group and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cellular Biomedicine Group||0||0||1||0||3.00|
|Cellular Biomedicine Group Competitors||758||3015||11129||227||2.72|
Cellular Biomedicine Group currently has a consensus price target of $18.00, indicating a potential upside of 87.50%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.72%. Given Cellular Biomedicine Group’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellular Biomedicine Group is more favorable than its peers.
Insider and Institutional Ownership
5.8% of Cellular Biomedicine Group shares are held by institutional investors. Comparatively, 51.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 8.2% of Cellular Biomedicine Group shares are held by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Cellular Biomedicine Group has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500. Comparatively, Cellular Biomedicine Group’s peers have a beta of 6.66, suggesting that their average share price is 566% more volatile than the S&P 500.
Valuation and Earnings
This table compares Cellular Biomedicine Group and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cellular Biomedicine Group||$229,178.00||-$22.45 million||-4.71|
|Cellular Biomedicine Group Competitors||$260.16 million||$66.28 million||-6.83|
Cellular Biomedicine Group’s peers have higher revenue and earnings than Cellular Biomedicine Group. Cellular Biomedicine Group is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Cellular Biomedicine Group peers beat Cellular Biomedicine Group on 7 of the 12 factors compared.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
Receive News & Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.